Biosimilars

Encyclopedia of Health Economics

Volumn , Issue , 2014, Pages 86-97

  Grabowski, H ^a   Long, G ^b   Mortimer, R ^b  

^a DUKE UNIVERSITY   (United States)

^b ANALYSIS GROUP   (United States)

Author keywords

Biologic; Biosimilar; Drug prices; Exclusivity; FDA approval; Healthcare costs; Innovation; Interchangeable; Patents; R D Costs; Reimbursement

Indexed keywords

EID: 84994084658     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-375678-7.01208-6     Document Type: Chapter

References (30)

1. Avalere Health (2007). Modeling federal cost savings from follow-on biologics (study author King, R.). (accessed 18.07.13). http://www.avalerehealth.net/research/docs/Follow_on_Biologic_Modeling_Framework.pdf.
2. Berndt E., Mortimer R., Bhattacharjya A., Parece A., Tuttle E. Authorized generic drugs, price competition, and consumers' welfare. Health Affairs 2007, 790:792-797.
3. Chauhan D., Towse A., Mestre-Ferrandiz J. The market for biosimilars: evolution and policy options. Office of Health and Economics Briefing 2008, 12-14.
4. Congressional Budget Office (CBO) (2008). S.1695, Biologics Price Competition and Innovation Act of 2007. Available at: (accessed 18.07.13). http://www.cbo.gov/sites/default/files/cbofiles/ftpdocs/94xx/doc9496/s1695.pdf.
5. DiMasi J., Grabowski H. The economics of new oncology drug development. Journal of Clinical Oncology 2007, 209:214-215.
6. DiMasi J., Grabowski H. The cost of biopharmaceutical R&D: Is biotech different?. Managerial & Decision Economics 2007, 469-475.
7. Express Scripts (2007). Potential savings of biogenerics in the United States (study authors Miller, S. and Houts, J.). (accessed 18.07.13). http://www.express-scripts.com/research/research/archive/docs/potentialSavingsBiogenericsUS.pdf.
8. Food and Drug Administration (FDA) (2012a). Scientific considerations in demonstrating biosimilarity to a reference product. Available at: (accessed 18.07.13). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf.
9. Food and Drug Administration (FDA) (2012b). Biosimilars: Questions and answers regarding implementation of the Biologics Price Competition and Innovation Act of 2009. Available at: (accessed 18.07.13). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM273001.pdf.
10. Federal Trade Commission (2002). Generic drug entry prior to patent expiration: An FTC study. Available at: (accessed 18.07.13). http://www.ftc.gov/os/2002/07/genericdrugstudy.pdf.
11. Grabowski, H. (2007). Competition between generic and branded drugs. In Sloan, F. A. and Hsieh, C-R. (eds.) Pharmaceutical innovation: Incentives, competition, and cost-benefit analysis in international perspective, pp. 153-173. New York, NY: Cambridge University Press.
12. Grabowski H. Follow-on biologics: Data exclusivity and the balance between innovation and competition. Nature Reviews Drug Discovery 2008, 479:479-487.
13. Grabowski H., Cockburn I., Long G. The market for follow-on biologics: How will it evolve?. Health Affairs 2006, 1291:1291-1301.
14. Grabowski H., Kyle M., Mortimer R., Long G., Kirson N. Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman Act. Health Affairs 2011, 30:2157-2166.
15. Grabowski H., Lewis T., Guha R., et al. Does generic entry always increase consumer welfare?. Food and Drug Law Journal. 2012.
16. Grabowski H., Long G., Mortimer R. Data exclusivity for biologics. Nature Reviews Drug Discovery 2011, 15:15-16.
17. Grabowski H., Ridley D., Schulman K. Entry and competition in generic biologics. Managerial & Decision Economics 2007, 28(4-5):439-447.
18. Grabowski H., Wang R. The quantity and quality of worldwide new drug introductions, 1982-2003. Health Affairs 2006, 25(2):452-460.
19. Hargrave, E., Hoadley, J., Merrell, K. (2010). Medicare Part D Formularies, 2006-2010: A Chartbook, Report to the MedicarePayment Advisory Commission. Available at: (accessed 18.07.13). http://www.medpac.gov/documents/Oct10_PartDFormulariesChartBook_CONTRACTOR_RS.pdf.
20. Heldman, P. (2008). Follow-on biologic market: Initial lessons and challenges ahead. Potomac Research Group, Presentation to the Federal Trade Commission. Available at: (accessed 18.07.13). http://www.ftc.gov/bc/workshops/hcbio/docs/fob/pheldman.pdf.
21. IMS (2011a). Shaping the biosimilars opportunity: A global perspective on the evolving biosimilars landscape. Available at: (accessed 18.07.13). http://www.imshealth.com/ims/Global/Content/Home%20Page%20Content/IMS%20News/Biosimilars_Whitepaper.pdf.
22. The Use of Medicines in the United States: Review of 2010 2011, IMS, IMS Institute for Healthcare Informatics, Available at: http://www.imshealth.com.
23. Kambhammettu, S. (2008). The European biosimilars market: Trends and key success factors. Scicast Special Reports. Available at: (accessed 18.07.13). http://scicasts.com/specialreports/20-biopharmaceuticals/2152-the-european-biosimilars-market-trends-and-key-success-factors.
24. Kozlowski S., Woodcock J., Midthun K., Behrman S.R. Developing the nation's biosimilar program. New England Journal of Medicine 2011, 364(5):385-388.
25. Smith I., Procter M., Gelber R.D., et al. 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomized controlled trial. Lancet 2007, 369(9555):29-36.
26. Sokolovsky, J., Miller, H. (2009). Medicare payment systems and follow-on biologics, Medicare Payment Advisory Commission. (accessed 18.07.13). http://www.medpac.gov/transcripts/followon%20biologics.pdf.
27. Trusheim M.R., Aitken M.L., Berndt E.R. Characterizing markets for biopharmaceutical innovations: do biologics differ from molecules?. Forum for Health Economics & Policy (Frontiers in Health Policy Research) 2010, 13(1):1-45. The Berkeley Electronic Press.
28. Weaver A.L. The impact of new biologicals in the treatment of rheumatoid arthritis. Rheumatology 2004, 43(Supplement 3):iii17-iii23.
29. Grabowski H., Long G., Mortimer R. Implementation of the biosimilar pathway: Economic and policy issues. Seton Hall Law Review 2011, 41(2):511-557.
30. Rovira, J., Espin, J., Garcia, L., and de Labry, A. O. (2011). The impact of biosimilars entry in EU markets. Andalusian School of Public Health. (accessed 18.07.13). http://ec.europa.eu.